Although patients with connective tissue diseaseassociated interstitial lung disease (CTD-ILD) and idiopathic pulmonary fibrosis (IPF) have been relatively well characterized, less is known about patients who have interstitial pneumonia (IP) and positive serologies for connective tissue disease (CTD) but do not meet established diagnostic criteria for CTD. [1] [2] [3] [4] This group has been described as undifferentiated CTD-ILD, autoimmune featured interstitial lung disease (ILD), lung dominant CTD, and most recently, interstitial pneumonia with autoimmune features (IPAF). [5] [6] [7] [8] [9] [10] The 2011 evidence-based guidelines, while giving precise criteria for IPF, acknowledge that patients with usual interstitial pneumonia (UIP) and autoantibodies who do not meet criteria for a specific CTD are considered to have IPF in the appropriate clinical setting. 2 IPAF, based on serologic, clinical, and morphologic domains, was recently proposed in a research statement intending to create a more homogenous population of patients with IP and characteristics of autoimmune disease without CTD. 10 However, IPAF excludes a group of patients with positive autoantibodies with or without symptoms of CTD and IP (UIP in particular) not fulfilling IPAF criteria.
Although the UIP pattern is relatively common among patients with CTD-ILD, such as rheumatoid arthritis, and in studies of patients with IP with autoimmune characteristics, such as lung dominant CTD, presence of UIP alone is not included in the IPAF morphologic domain. 9, 11 This does not mean that all patients with UIP are excluded from IPAF, but rather that UIP alone does not fulfill the IPAF morphologic domain. Therefore, a patient without one of seven symptoms in the IPAF clinical domain with positive autoantibodies and UIP would not currently be included in IPAF and presumably would be considered to have IPF.
Acknowledging that the proposed IPAF criteria were consensus based, we think the proposed IPAF criteria should be broadened to include such a patient, or perhaps categorize such a patient as having autoimmune interstitial lung disease (AI-ILD). 12 We sought to describe patients with AI-ILD and how these patients may or may not differ from those with IPAF in particular and from those with CTD-ILD and IPF with negative CTD serologies (Lone-IPF) by describing demographics, pattern of IP, and change in pulmonary function over time.
Methods

Study Design, Setting, and Subjects
This is a retrospective cohort study of adult patients seen at the Center for Interstitial Lung Diseases (CILD), at a tertiary referral center, at the University of Washington Medical Center (UWMC), from January 1, 2007 to March 31, 2013. All patients presenting to the CILD for new evaluation/management of ILD during the study period were screened. Four prespecified groups were identified (Table 1) . Patients with IP and autoimmune characteristics were classified as (1) IPAF or (2) AI-ILD according to criteria in Table 1; groups 3 and 4 were CTD-ILD and IPF, respectively. 2, 8, 10 In addition to meeting 2011 guideline criteria, to meet criteria for IPF in our cohort, negative CTD serologies were required (Lone-IPF). The UWMC institutional review board approved this study (No. 44852).
Inclusion Criteria
Eligible patients were $ 18 years of age and had IP based on highresolution CT images of the chest (inhalation/expiration images and supine/prone images). To avoid confounding and variability associated with testing technique and reference values between laboratories, we only included patients who had pulmonary function tests (PFTs) performed at the UWMC at initial CILD evaluation and 12 months later and who had serologic testing for CTD (all had antinuclear antibodies/patterns by immunofluorescence assay with reflexive panel, including anti-Sjogren syndrome related antigen A, anti-Sjogren syndrome related antigen B, antitopoisomerase 1, and antihistadyl-tRNA synthetase; rheumatoid factor; anticyclic citrullinated peptide antibody; and if available antineutrophil cytoplasmic antibody panel and myositis panel) at the UWMC Immunology Laboratory.
Exclusion Criteria
Patients with alternative explanations for ILD (eg, hypersensitivity pneumonitis, radiation treatment, drug-induced, occupationassociated, sarcoidosis), coexisting obstructive lung disease (FEV 1 / FVC < 0.70), and emphysema greater than ILD on high-resolution CT chest images and comorbid lung conditions (eg, lung neoplasm, asthma, COPD) were excluded.
Outcomes
The outcomes of the study were the differences in mean change in absolute and percent predicted FVC and diffusion capacity (DLCO) (corrected for hemoglobin) between 0 and 12 months.
Potential Confounding Factors
Potential confounding factors included age, sex, prior/current tobacco smoking, pulmonary hypertension by transesophageal echocardiogram or right heart catheterization, and abnormal acid gastroesophageal reflux by pH probe.
Statistical Analyses
Hypothesis tests were performed to compare outcomes between the groups (IPAF, AI-ILD, CTD-ILD, and Lone-IPF). Analysis of variance was used to compare change in means, and Pearson c 2 test or Fisher exact test was used to compare proportions. For each patient, the difference in FVC or DLCO between 0 and 12 months was calculated, and then the mean of these values was calculated and reported. If there was a statistically significant difference in overall group comparison, additional testing was performed to compare individual groups with each other. To protect against inflation of type I error, Tukey honest significant difference method (means), or the Bonferroni method (proportions), were used. Statistical significance was indicated for P < .05. Linear regression analyses adjusted for potential confounding covariates (age, sex, pulmonary hypertension, and outcome value at initial visit) were also performed. All statistical analyses were completed using SPSS 19.0 (IBM) and R version 3.1 (R Foundation for Statistical Computing).
Results
Cohort
Between January 2007 and March 2013, 124 patients (IPAF: n ¼ 15, AI-ILD: n ¼ 20, CTD-ILD: n ¼ 36, and Lone-IPF: n ¼ 52) referred to CILD met strict inclusion criteria. Table 2 shows the pattern of IP, serologic data, and symptoms for patients with AI-ILD. Most patients with AI-ILD had a UIP pattern of disease. These patients did not have detectable signs/symptoms of CTD that would fulfill the IPAF clinical domain other than joint pain, but this was attributed to degenerative joint disease because it was not clearly described as inflammatory in nature.
Demographic characteristics of all four groups are shown in Table 3 . Overall, 53% of patients with IPAF, 40% with AI-ILD, 17% with CTD-ILD, and 62% with Lone-IPF were men (P < .01). Among patients in the CTD-ILD group, scleroderma spectrum disease and rheumatoid arthritis were the most common, accounting for 37.1% and 22.9%, respectively (data not shown). Patients with CTD-ILD were more often women than patients with IPAF and patients with Lone-IPF. On average, patients with Lone-IPF were older than those with IPAF and CTD-ILD, and those with AI-ILD were on average older than those with CTD-ILD (Table 3 ). More patients with Lone-IPF and AI-ILD were former/current smokers than those with chestjournal.org IPAF and CTD-ILD, but these differences were not statistically significant. The proportion of patients with pulmonary hypertension and gastroesophageal reflux disease did not differ significantly between the four groups. Initial FVC and DLCO percent predicted were similar, and on average FVC was mildly reduced and DLCO was moderately reduced.
Pattern of ILD
All patients had high-resolution CT chest images. ILD pattern was assessed by histopathology (surgical lung biopsy) in 80% of patients with IPAF, 35% with AI-ILD, 41.7% with CTD-ILD, and 75.5% with Lone-IPF. UIP was observed in all patients with Lone-IPF and most patients with AI-ILD (75%). Nonspecific interstitial pneumonia (NSIP) or an unclassifiable/ other pattern was observed in most patients with IPAF and CTD-ILD (Table 4 ). The pattern of IP did not differ significantly between patients with CTD-ILD and IPAF, but did differ between patients with AI-ILD (75% with UIP) and CTD-ILD (33% with UIP; P ¼ .04). Joint pains were not specifically described as inflammatory in nature and were therefore assumed to be more consistent with osteoarthritis/degenerative changes.
Difference in Pulmonary Physiology at 0 and 12 Months
Mean change in FVC over 12 months ranged from À113 mL (AI-ILD) to À11 mL (CTD-ILD) (P ¼ .70) ( Tables 5, 6 ). Changes in FVC percent predicted over 12 months did not differ significantly between groups on unadjusted (analysis of variance) or adjusted analyses (linear regression) ( Tables 5, 6 ). Mean change in DLCO and DLCO percent predicted over 12 months significantly differed between IPAF and each of the other groups on both unadjusted and adjusted analyses. There were not significant differences in mean change in DLCO or DLCO percent predicted between AI-ILD, CTD-ILD, and Lone-IPF on post hoc testing (Tables 5, 6 ).
We assessed for differences in mean change in FVC over 12 months between patients with UIP, NSIP, and other/unclassifiable patterns of IP (regardless of whether patients had IPAF, AI-ILD, CTD-ILD, or Lone-IPF) and found a mean change in FVC over 12 months chestjournal.org of À135 mL among patients with the UIP pattern, which was significantly greater than the mean change in FVC in patients with NSIP or other/unclassifiable pattern ( Table 7) . Patients with UIP also had a greater decrease in mean change in DLCO over 12 months than those with other/unclassifiable pattern.
Finally, we performed a subanalysis to assess for differences in mean change in FVC and DLCO among only those patients with UIP in each of the four groups (IPAF with UIP: n ¼ 5, AI-ILD with UIP: n ¼ 15, CTD-ILD with UIP: n ¼ 12, and IPF with UIP: n ¼ 52). Overall results were unchanged from those previously mentioned (data not shown). We also compared patients within each group (AI-ILD, IPAF, and CTD-ILD) with UIP with those with non-UIP and did not find significant differences in mean change in FVC and DLCO over 12 months (Table 8) . Post hoc tests (Tukey honest significant difference) showed IPAF significantly different from all other groups in DLCO (P < .001) and DLCO percent predicted (P ¼ .01). 
Discussion
The IPAF criteria were introduced to characterize patients with IP and autoimmune characteristics for research purposes, and efforts to validate these criteria are ongoing prior to recommendation for use in routine clinical practice. [13] [14] [15] The proposed consensus-based criteria exclude some patients, particularly those with UIP (which does not fulfill the IPAF morphologic domain), with ILD and positive serologies who may have characteristics of CTD but do not meet one of Post hoc tests (Tukey honest significant difference) showed no significant differences between any pair of groups. See Table 1 and 5 legends for expansion of abbreviations.
chestjournal.org seven clinical criteria in the IPAF clinical domain. 10 It is unknown if the patients we characterized as AI-ILD (IP and positive CTD serologies with or without symptoms suggestive of CTD not meeting IPAF criteria) will blossom into a specific CTD later in their course, if AI-ILD is a distinct phenotype, or if these positive autoantibodies are clinically insignificant. To our knowledge, this study is the first large case series to describe and compare mean change in FVC and DLCO over 1 year in a well-defined cohorts of patients with IPAF, CTD-ILD, and Lone-IPF with AI-ILD.
We did not find significant differences in demographics to distinguish one group from another, other than patients with IPAF and CTD-ILD tended to be younger than those with AI-ILD and Lone-IPF. We also did not observe a clinically significant difference in mean change in pulmonary function over 1 year when comparing patients with IPAF, AI-ILD, CTD-ILD, and Lone-IPF.
We observed an incremental increase in DLCO over 12 months among patients with IPAF, whereas DLCO decreased among patients with AI-ILD, CTD-ILD, and Lone-IPF on both adjusted and unadjusted analyses. Although this finding could suggest a trend supporting distinction of patients with IPAF from those in the other three groups, in particular AI-ILD, the differences we observed are arguably small to be clinically significant, given inherent variability in DLCO measurements and lack of significant differences in FVC measurements. 2, 16, 17 Among patients with IP and an autoimmune flavor to their disease in our cohort, 43% met criteria for IPAF, and the remaining 57% were classified as AI-ILD. Some patients with AI-ILD did have symptoms with an autoimmune flavor (eg, esophageal dysmotility; muscle aches, pain, and some weakness) that were not included in the proposed clinical domain of IPAF. We consider these patients as AI-ILD, distinguishing them from patients with true IIP or IPF. Others did not have symptoms suggestive of CTD and merely had positive autoantibodies, which would meet criteria for IPF diagnosis based on the current guidelines. Limitations include the retrospective and observational nature of this single-center study, albeit a center with recognized expertise in evaluation and management of ILD. There is selection bias because we deliberately included only patients with all PFTs and serologic testing performed at our center. Although this greatly reduced the sample size to a relatively small proportion of the large number of patients seen at CILD during the study period, we took this approach to ensure consistency of PFT technique, reference values, and adherence to American Thoracic Society standards over time and allow accurate comparison within patients and between groups. Finally, the study design and sample size of the cohorts do not allow meaningful conclusions to be drawn regarding treatment effects or mortality; however, multiple clinical trials of ILD in the setting of scleroderma and IPF have used an end point of change in FVC over 1 year. [31] [32] [33] [34] [35] An additional limitation is that only a proportion of patients with AI-ILD were formally evaluated by a rheumatologist at the UWMC for confirmation/evaluation of their rheumatologic symptoms, if present. Specific information from the patients who may have been evaluated by an outside rheumatologist was not available to us. Finally, although patients entered the cohort at the time of initial presentation to the CILD, patients were not at a uniform point in their disease course or duration of symptoms; some were newly diagnosed, and others had been previously diagnosed and were presenting for further evaluation and management recommendations.
Conclusions
Our results suggest that patients with AI-ILD more closely resemble those with IPF than those with IPAF. Given the small numbers and small differences in change in pulmonary function over time that are likely not clinically significant, we did not find evidence to support exclusion of patients with AI-ILD from studies of those with IIP and an autoimmune flavor to their disease. Our results suggest that further study over longer periods of time is necessary prior to exclusion of patients with AI-ILD from future studies of patients with IPAF. It is important to study patients with phenotypes that are less clear because patients with idiopathic NSIP or cryptogenic organizing pneumonia are often already treated with immunomodulatory therapies. In the interim, we believe patients with AI-ILD should be included in ongoing and future studies aiming to understand clinical course and outcomes of patients with IP and an autoimmune flavor to their disease rather than placed in the category of IPF or IP by default.
chestjournal.org
